Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Mona Shing
Adjuvant Subcutaneous Trastuzumab for HER2‐Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study
Oncologist
Cancer Research
Medicine
Oncology
Related publications
Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
New England Journal of Medicine
Medicine
Cost-Utility Analysis of Adjuvant Trastuzumab Therapy for HER2-positive Early-Stage Breast Cancer in the Philippines
BMC Health Services Research
Health Policy
Trastuzumab as Adjuvant Treatment for Early Stage HER2-positive Breast Cancer — A 10 Year History
Nowotwory
Cancer Research
Oncology
Pcn74 - A Budget-Impact Analysis of Adjuvant Pertuzumab and Trastuzumab in Early Her2-Positive Breast Cancer
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer
JAMA Oncology
Cancer Research
Oncology
Efficacy and Safety of CT-P6 Versus Reference Trastuzumab in HER2-positive Early Breast Cancer: Updated Results of a Randomised Phase 3 Trial
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
Relationship Between Tumor Biomarkers and Efficacy in MARIANNE, a Phase III Study of Trastuzumab Emtansine ± Pertuzumab Versus Trastuzumab Plus Taxane in HER2-positive Advanced Breast Cancer
BMC Cancer
Cancer Research
Oncology
Genetics
Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer
Clinical Breast Cancer
Cancer Research
Oncology
Pcn20 - Contribution of Trastuzumab to the Prognostic Improvement of Her2-Positive Early Breast Cancer in Spain
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental